ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

NCT03922555 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Neurological Cancer

Interventions

DRUG: ASTX727

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]